Abstract 12813: Elevated Soluble CD93 Levels and Their Relationship With Clinical Outcomes in Patients With Acute Myocardial Infarction
Background: CD93 is a 68kDa transmembrane glycoprotein and is expressed in monocytes, leukocytes and endothelial cells. CD93 is overexpressed upon inflammatory stimulation, and its soluble form (sCD93) is known to be increased in inflammatory status. We hypothesized that circulating levels of sCD93 is increased and associated with clinical outcomes in acute myocardial infarction (MI) patients.
Methods: We measured circulating levels of sCD93 in 120 patients with acute MI (62.6±12.8 yrs, M:F=85:35) and in age, sex-matched 120 control subjects. In acute MI patient, clinical characteristics, echocardiographic and laboratory findings were assessed at the time of initial enrollment. The primary outcome was defined as all-cause and cardiovascular death.
Results: Circulating sCD93 levels were significantly higher in patients with acute MI than in control subjects (552.1±293.7ng/mL vs. 429.8±114.2ng/mL, p<0.0001). During follow up period (median 208 days, 3-1058 days), the primary outcome had occurred in 18 (15%) patients (9 cardiovascular deaths). Circulating levels of sCD93 are associated with all cause (p=0.0001) and cardiovascular (p=0.0014) mortality in acute MI patients. Multivariate cox regression analysis revealed that initial sCD93 level was found to be an independent predictor of all cause (p=0.002) and cardiovascular mortality (p=0.033) when controlled for age, LVEF.
Conclusions: Circulating levels of sCD93 are elevated in patients with acute MI and their levels were associated with clinical outcomes.
- © 2011 by American Heart Association, Inc.